Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.49 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.48 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.47 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225688 | 0.85 | SLC16A3 (0.59) | PTGS2CA1CA2CA9SLC16A3 | |
| SCHEMBL4964542 | 0.82 | PTGS2 (0.60) | PTGS2PTGS1SLC16A3SLC16A1MCTS1 | |
| SCHEMBL3864236 | 0.82 | PTGS2 (0.90) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL4958833 | 0.80 | MALT1 (0.56) | PTGS2PTGS1SLC16A3SLC16A1MCTS1 | |
| SCHEMBL9941289 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL18301051 | 0.76 | SLC16A3 (0.65) | PTGS2SLC16A3SLC16A1MCTS1MALT1 | |
| SCHEMBL4960172 | 0.76 | PTGS2 (0.52) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL3867856 | 0.75 | PTGS2 (0.78) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL3940435 | 0.74 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL3869730 | 0.73 | CA1 (0.80) | PTGS2PTGS1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | claimed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | claimed |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITRODMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885PTGS1 4/4885CA1 3581/4885 |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGS1 | PTGS2 1/4885PTGS1 3/4885CA1 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.